Disease heterogeneity, prognostication and the role of targeted therapy in multiple myeloma

Saurabh Zanwar, Shaji Kumar

Research output: Contribution to journalReview articlepeer-review

Abstract

Multiple myeloma (MM) is a clonal plasma cell malignancy with a heterogeneous disease course. Insights into the genetics of the disease have identified certain high-risk cytogenetic features that are associated with adverse outcomes. While the advances in therapy have translated into dramatic improvements in the outcome of patients with MM, those with high-risk genetic features continue to perform poorly. This has resulted in a need for clinical trials focusing on the high-risk subgroup of MM as they search for additional biomarkers and therapeutic targets continue. In this review, we discuss the currently existing data on prognostic and predictive biomarkers in MM and speculate the role of treatment stratification based on the genetic features of the disease.

Original languageEnglish (US)
Pages (from-to)3087-3097
Number of pages11
JournalLeukemia and Lymphoma
Volume62
Issue number13
DOIs
StatePublished - 2021

Keywords

  • cytogenetics
  • Gene expression profiling
  • high risk
  • mutations
  • personalized therapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Disease heterogeneity, prognostication and the role of targeted therapy in multiple myeloma'. Together they form a unique fingerprint.

Cite this